Introduction
============

Progesterone is considered to play a major role in the maintenance of pregnancy. In 1956 Csapo proposed that the essential role of progesterone in pregnancy is to 'block' myometrial contractility and that the onset of labour therefore requires withdrawal of this progesterone block. In the majority of mammals labour is preceded by a decline in circulating progesterone concentrations, however, in the human, there is no dramatic fall in progesterone concentrations prior to labour, yet parturition can be induced using progesterone antagonists. This has led to the concept that, in the human, labour is associated with 'functional progesterone withdrawal' caused through changes in the expression or function of PR rather than through changes in circulating concentrations of progesterone \[[@b1], [@b2]\].

The genomic effects of progesterone upon target tissues are generally mediated through nuclear PR. The major PR isoforms, PR-A and PR-B, are encoded from a single gene by differential promoter usage. PR-A, a 94 kD protein, lacks the first N-terminal 164 amino acids of PR-B, which is a 116 kD protein with an additional activation function (AF-3) \[[@b1], [@b2]\]. In myometrial cells, PR-A has limited transactivation properties at classical progesterone response elements and has been shown to transrepress PR-B and other class I nuclear receptor family members \[[@b3], [@b4]\]. The PR gene also contains additional putative downstream translational start sites predicted to encode proteins of approximately 60--70 and 39 kD respectively. A 60 kD PR variant found in T47D cells has been termed PR-C. This contains a ligand-binding domain, but lacks a DNA binding domain and has been reported to be cytosolic rather than nuclear \[[@b5]\].

A current theory for the mechanism of 'functional progesterone withdrawal' in human myometrium involves a change in the abundance of PR isoforms, leading to a decrease in the ratio of PR-B to PR-A and/or PR-C \[[@b1], [@b2], [@b4]\]. Other proposed mechanisms include a decline in the myometrial levels of PR coactivators at term \[[@b6]\], and a decrease in the circulating concentration of bioactive progesterone metabolites associated with decreased steroid 5 beta-reductase expression in the uterus \[[@b7]\].

A further potential mechanism for 'functional progesterone withdrawal' in the human involves the transcriptional antagonism between the activated PR and inflammatory signal intermediates, especially the inflammation-associated transcription factor NF-kappaB (NF-κB). A central role for NF-κB in murine parturition has been demonstrated \[[@b8]\]. Nuclear translocation of the p50 and p65 subunits of NF-κB increases in the pregnant mouse uterus towards term and intra-amniotic injection of the NF-κB inhibitor peptide SN50 delays in the onset of labour. Surfactant protein-A (SP-A), secreted by the maturing foetus lung in increasing amounts towards term, was shown to enhance p65 nuclear levels and to induce labour. It has been proposed that SP-A triggers the onset of labour at term by inducing the migration of macrophages to the maternal uterus, where local inflammatory signals activate NF-κB signalling in myocytes, resulting in the stimulation of uterine contractility. Direct protein-protein interaction between p65 and PR, resulting in reciprocal functional antagonism, has been demonstrated in breast cancer cells \[[@b9]\], and may also operate in uterine cells \[[@b10], [@b11]\].

Activation of myometrial inflammation, or more specificially of the NF-κB pathway in the myometrium appears to be an attractive mechanism to account for 'functional progesterone withdrawal' at term. However, the functional consequences of the interaction between PR and NF-κB on myometrial gene expression in pregnancy has not yet been determined. We have therefore combined small interfering (si)RNA-mediated knock-down of PR in human term pregnant myocytes with whole genome microarray analysis to identify those genes regulated by activated PR. We then used IL-1β stimulation, which activates NF-κB and induces myometrial inflammation, to determine the role of PR in the transcriptional regulation of myometrial inflammation.

Materials and methods
=====================

Tissue collection and cell culture
----------------------------------

Tissue was collected with local ethics committee approval and informed consent from patients at Queen Charlotte\'s and Chelsea Hospital, London. Myometrial tissue was obtained from the upper edge of lower uterine incision, made at the location of the bladder fold at the time of Caesarean section. Elective caesarean section was performed in each case at or after 39 weeks in uncomplicated pregnancies. Indications were breech presentation and previous caesarean section. Myometrial tissue was minced and digested for 45 min. in DMEM with 1 mg/ml collagenase type IA and IX (Sigma-Aldrich Company Ltd, Poole, UK). Cells were centrifuged at 400 × *g* for 10 min. and grown in DMEM with 10% foetal calf serum, [l]{.smallcaps}-glutamine and penicillin-streptomycin (37°C and 5% CO~2~)~.~ Cells (passage number 3 or 4) were incubated with 100nM medroxyprogesterone acetate (MPA) in 2% reduced serum for 24 hrs before IL-1β (R&D Systems, Europe Ltd., Abingdon, UK) was added to a final concentration of 1 ng/ml for 6 hrs. To confirm that the cells established in our cultures are myocytes and not fibroblasts or epithelial cells, we undertook Western analysis for alpha-smooth-muscle actin, and oxytocin receptor and found no significant changes in expression between passages 0--4 ([Fig. 1](#fig01){ref-type="fig"}A).

![(A) Expression of oxytocin receptor (OTR), alpha-smooth muscle actin (aSMA) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) at passage numbers zero through four. (B) Expression of PRB and PRA measured by Western analysis in cultured human myocytes in non-transfected (control), non-targeting siRNA transfected (NT) and PR targeting siRNA transfected (siPR) cells. Blots were scanned for densitometric analysis, values were normalized for GAPDH and are expressed as arbitrary units. One example blot is shown. Graphs *n* = 6 ± S.E., \**P* \< 0.05 compared with control. (C) Expression of PRB and PRA and of Ser536-P-p65 (NF-kappaB p65) measured by Western analysis in cultured human myocytes in controls incubated with MPA (100 nM) (control) and following incubation with MPA (100 nM) and IL1B (1 ng/ml) for up to 24 hrs. Blots were scanned for densitometric analysis, values were normalized for GAPDH and are expressed as arbitrary units. One example blot is shown. Graphs *n* = 4 ± S.E. \**P* \< 0.05 compared with control. (D) Validation experiments measuring expression of selected genes in myocytes in culture following siRNA knock-down of PR (siPR N/S), incubation with and without IL1B (1 ng/ml) (NT + IL1B), or both together (siPR + IL1B), compared with non-targeting siRNA transfected (NT) control. Black bars show qRT-PCR validation data (*n* = 4 ± S.E. \**P* \< 0.05 compared with control). Grey bars show data from microarray for comparison.](jcmm0016-2487-f1){#fig01}

Transfection of siRNA
---------------------

ON-TARGETplus SMART pool human RNA (Dharmacon, Lafayette, CO, USA) was used to knock-down PR. SiGLO (Dharmacon) was used as a positive control, giving a high transfection efficiency of approximately 90%, and ON-TARGETplus Non-Targeting Pool (Dharmacon) was used as a negative control. The siRNAs were transfected using Dharmafect 2 (Dharmacon) transfection reagent at a final concentration of 20 μM according to manufacturer\'s instructions.

Protein extraction
------------------

Myocytes were scraped into buffer A \[10 mM HEPES pH 7.4, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT, complete protease inhibitor tablets (Roche, Welwyn Garden City, UK) and 2 M KOH to adjust pH to 7.4\]. The resulting suspension was collected and incubated on ice for 20 min. To the incubated mixture, NP-40 (Nonidet P-40, Sigma-Aldrich Company Ltd) was added to give a final concentration of 1% and carefully mixed. The cytosolic protein fraction was extracted by centrifuging at 13,000 × *g* for 30 sec. The pellet was then resuspended in buffer B (10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT, 400 mM NaCl, 1% NP-40) and complete protease inhibitor tablets (Roche) to lyse the nuclear membrane. Samples were incubated on a shaking platform for 15 min. Cell suspensions were centrifuged at 13,000 × *g* for 5 min. and supernatant (nuclear protein fraction) was collected, snap-frozen and stored at −80°C for later use.

Western blot analysis
---------------------

A quantity of 50μg protein samples were mixed with Laemmli sample buffer (1:1) containing beta-mercaptoethanol (5%), and boiled for 5 min. Protein was separated by SDS-PAGE gels and transferred onto nitrocellulose membrane (Amersham Biosciences, Amersham, UK). The membrane was blocked in buffer containing 5% milk powder, PBS and 0.1% Tween 20 for 30 min., and immunoblotted with primary antibody for 1 hr in 1% milk buffer followed by secondary antibody for 45 min. Horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Heidelberg, Germany) was used with ECL Plus (Amersham Biosciences) chemiluminescent reagents for signal detection. Antibodies used were PR Novocastra NCL-L-PGR-312 (Novocastra Laboratories Ltd, Newcastle upon Tyne, UK) OTR Santa Cruz SC-8102, alpha smooth muscle actin Sigma A2547, GAPDH Millipore MAB374, Millipore, Watford, UK, beta actin Abcam ab8226 (Abcam, Cambridge, UK) and NFkB pp65 Serine 536 Cell Signalling 3033S (Cell Signaling Technology, New England Biolabs, Hitchin, UK).

RNA extraction
--------------

Total RNAs were isolated using Trizol (Invitrogen, Paisley, UK) according to the manufacturer\'s protocol and further purified using the RNeasy mini Kit (QIAGEN, Crawley, UK). RNA integrity and purity were assessed using a Bioanalyzer 2100 (Agilent Technologies Inc., Santa Clara, CA, USA).

Quantitative real time polymerase chain reaction (RTQ-PCR)
----------------------------------------------------------

Total RNA 1 μg was reverse transcribed with oligo dT random primers using MuLV reverse transcriptase (Applied Biosystems Ltd, Carlsbad, CA, USA). Paired oligonucleotide primers for amplification of genes of interest were designed using Primer 3 software (<http://www.ncbi.nlm.nih.gov/tools/primer-blast/>) against the sequences downloaded from GenBank. The primer sets used ([Table 1](#tbl1){ref-type="table"}) produced amplicons of the expected size and where possible flanked intron/exon junctions. Quantitative PCR was performed using Power SYBR Green PCR master mix (Applied Biosystems Ltd.,) and amplicon yield was monitored during cycling in a RotorGene Sequence Detector (Corbett Research Ltd.) that continually measures fluorescence caused by the binding of the dye to double-stranded DNA. Pre-PCR cycle was 10 min. at 95°C followed by up to 45 cycles of 95°C for 20 sec., 58--60°C for 20 sec. and 72°Cfor 20 sec. followed by an extension at 72°C for 15 sec. The final procedure involves a melt over the temperature range of 72--99°C rising by 1 degree steps with a wait for 15 sec. on the first step followed by a wait of 5 sec. for each subsequent step. The cycle at which the fluorescence reached a preset threshold (cycle threshold) was used for quantitative analyses. The cycle threshold in each assay was set at a level where the exponential increase in amplicon abundance was approximately parallel between all samples. mRNA data were expressed relative to the amount of the constitutively expressed housekeeping gene, GAPDH.

###### 

Sequences for PCR primers used in quantitative RT-PCR validation studies

  Gene symbol   Forward primer (5′--3′)     Reverse primer (5′--3′)
  ------------- --------------------------- -------------------------
  MMP1          CAGAGGGAGCTTCCTAGCTG        AGCTGTGCATACTGGCCTTT
  MMP3          CACTCACAGACCTGACTCGG        AGTCAGGGGGAGGTCCATAG
  MMP10         CAAAATCTGTTCCTTCGGGA        TCTCCCCTCAGAGTGCTGAT
  COLEC12       CAGCCAGCTCAACTCATTCA        GGTCTTTCAGGTTCTGCTCG
  STMN2         AAGAAAGTCTCAGGAGGCCC        TGTTGTTCTCCTCCAAAGCC
  SCARA3        AGGAGAGGGCAGAGGAAGAC        TGCCCAGAGACAGATGTGAG
  THBS1F        ACCAAAGCCTGCAAGAAAGA        TCTGTACCCCTCCTCCACAG
  KCNJ2         CGCTTTTTACAAACCACTGGA       AACATGTCCTGTTGCTGGC
  COL12A1       TGGAAAATCCCAGGATGAAG        CAGCTTTAATGCCCAAGGAG
  RXFP1         TCACCTCAGTCGAATTTCCC        TCAGGTAAACGGGTGAGGAC
  TRPC6         AGAAGTCGAGGCCATTCTGA        GAACTTGACCGCCATTGTCT
  PR            AGCCCACAATACAGCTTCGAG       TTTCGACCTCCAAGGACCAT
  GAPDH         TGATGACATCAAGAAGGTGGTGAAG   TCCTTGGAGGCCATGTAGGCCAT

Affymetrix HgU133 Plus 2.0 array processing
-------------------------------------------

RNA Samples were profiled by the Finnish DNA-Microarray Centre using the Affymetrix HgU133 Plus 2.0 GeneChip® (Affymetrix Inc., Santa Clara, CA, USA). Briefly, cDNA was generated from 2 μg of total RNA using the GeneChip® Expression 3′-Amplification One-Cycle cDNA Synthesis kit, in conjunction with the GeneChip® Eukaryotic PolyA RNA Control Kit (Affymetrix Inc.). The cDNA was cleaned up using the GeneChip® Sample Cleanup Module and subsequently processed to generate biotin-labelled cRNA using the GeneChip® Expression 3′-Amplification IVT Labelling Kit (Affymetrix Inc.). A quantity of 25 μg of labelled cRNA was fragmented using 5X fragmentation buffer and Rnase-free water at 94°C for 35 min. A quqntity of 15 μg of the fragmented, biotin-labelled cRNA was made up in a hybridization cocktail and hybridized to the HgU133 Plus 2.0 array at 45°C for 16 h. Following hybridization the arrays were washed and stained using the Affymetrix Fluidics Station 450 and scanned using the Affymetrix GeneChip® Scanner 3000. All steps of the process were quality controlled by measuring yield (μg), concentration (μg/l) and 260:280 ratios *via* spectrophotometry using the Nanodrop ND-1000 and sample integrity using the Agilent 2100 bioanalyser (Agilent Technologies Inc.).

Results
=======

PR regulates gene networks involved in myometrial quiescence and extracellular matrix integrity
-----------------------------------------------------------------------------------------------

To identify genes regulated in human myometrium by liganded PR, primary myocyte cultures were transfected with siRNA targeting PR or non-targeting control siRNA, and then incubated with medroxyprogesterone acetate (MPA; 100 nM) for 24 hrs. Cells were lysed, mRNA extracted and subjected to genome-wide expression profiling using Affymetrix HgU133 Plus 2.0 GeneChip® (Affymetrix Inc.). Targeting PR using siRNA resulted in greater than 80% knock-down of PR-B and PR-A expression at protein level on Western analysis ([Fig. 1](#fig01){ref-type="fig"}B).

The microarray data were filtered for significant changes in expression (*P* \< 0.05 after correction for multiple testing). Overall, 354 probe sets showed a significant change in expression upon PR-knock-down. Of these, 150 probes sets were increased and 204 decreased. When unannotated sequences and duplicate probe sets were eliminated, 159 (57%) and 118 (43%) unique gene sequences were increased and decreased, respectively, upon knock-down of PR. A total of 44 genes were ≥2-fold downregulated, of which only 11 transcripts were inhibited by ≥3-fold ([Table 2](#tbl2){ref-type="table"}). As PR-knock-down decreased the expression of these genes, they represent genes upregulated in a PR-dependent manner.

###### 

Unique genes whose expression was decreased by PR-knock-down, and whose expression is therefore upregulated by PR in the presence of progesterone. 44 genes showed changes in expression of 2-fold or more. 11 genes showed changes in expression of 3-fold or more. In each case *n* = 4, *P* \< 0.0005, Adjusted *P* \< 0.05)

  ID              Gene symbol   Gene title                                                     Fold change in expression
  --------------- ------------- -------------------------------------------------------------- ---------------------------
  222853_at       FLRT3         Fibronectin leucine-rich transmembrane protein 3               −5.419
  217287_s\_at    TRPC6         Transient receptor potential cation channel C6                 −5.406
  202708_s\_at    HIST2H2BE     Histone cluster 2, H2be                                        −4.98
  223877_at       C1QTNF7       C1q and tumour necrosis factor related protein 7               −4.545
  1559114_a\_at   CXCR7         CXC chemokine receptor type 7                                  −4.348
  206765_at       KCNJ2         Potassium inwardly rectifying channel, subfamily J, member 2   −4.138
  239710_at       FIGN          Fidgetin                                                       −4.069
  201107_s\_at    THBS1         Thrombospondin 1                                               −3.921
  235371_at       GLT8D4        Glycosyltransferase 8 domain containing 4                      −3.448
  231186_at       FLJ43390      Hypothetical LOC646113                                         −3.196
  202016_at       MEST          Mesoderm specific transcript homologue                         −3.153
  233109_at       COL12A1       Collagen type XII alpha-1 precursor                            −2.869
  226610_at       CENPV         Centromere protein V                                           −2.781
  204837_at       MTMR9         Myotubularin related protein 9                                 −2.748
  225008_at       ASPH          Aspartyl(asparaginyl)beta-hydroxylase                          −2.612
  201487_at       CTSC          Cathepsin C                                                    −2.411
  238447_at       RBMS3         RNA binding motif, single stranded interacting protein         −2.41
  222771_s\_at    MYEF2         Myelin expression factor 2                                     −2.402
  211959_at       IGFBP5        Insulin-like growth factor binding protein 5                   −2.384
  220153_at       ENTPD7        Ectonucleoside triphosphate diphosphohydrolase 7               −2.383
  224613_s\_at    DNAJC5        DnaJ (Hsp40) homologue, subfamily C, member 5                  −2.369
  208903_at       RPS28         Ribosomal protein S28                                          −2.367
  224767_at       RPL37         Ribosomal protein L37, mRNA                                    −2.357
  205807_s\_at    TUFT1         Tuftelin 1                                                     −2.342
  224984_at       NFAT5         Nuclear factor of activated T-cells 5, tonicity-responsive     −2.335
  222582_at       PRKAG2        Protein kinase, AMP-activated, gamma 2 non-catalytic subunit   −2.314
  223155_at       HDHD2         Haloacid dehalogenase-like hydrolase domain containing 2       −2.311
  202091_at       ARL2BP        ADP-ribosylation factor-like 2 binding protein                 −2.284
  213223_at       RPL28         Ribosomal protein L28                                          −2.236
  213024_at       TMF1          TATA element modulatory factor 1                               −2.217
  205012_s\_at    HAGH          Hydroxyacylglutathione hydrolase                               −2.196
  1554489_a\_at   CEP70         Centrosomal protein 70 kD                                      −2.17
  218888_s\_at    NETO2         Neuropilin (NRP) and tolloid (TLL)-like 2                      −2.163
  229456_s\_at    DDAH1         Dimethylarginine dimethylaminohydrolase 1 (DDAH1) V2           −2.154
  203854_at       CFI           Complement factor I                                            −2.128
  204042_at       WASF3         WAS protein family, member 3                                   −2.122
  215506_s\_at    DIRAS3        DIRAS family, GTP-binding RAS-like 3                           −2.116
  201285_at       MKRN1         Makorin ring finger protein 1                                  −2.093
  212875_s\_at    C2CD2         C2 calcium-dependent domain containing 2                       −2.084
  224727_at       C19orf63      Chromosome 19 open reading frame 63                            −2.082
  209066_x\_at    UQCRB         Ubiquinol-cytochrome c reductase binding protein               −2.027
  224559_at       MALAT1        Metastasis associated lung adenocarcinoma transcript 1         −2.01
  205381_at       LRRC17        leucine rich repeat containing 17                              −2.008
  205755_at       ITIH3         Inter-alpha (globulin) inhibitor H3                            −2.003

Of the 159 genes upregulated in response to PR knock-down, 79 increased by ≥2-fold, including 24 that were induced ≥3-fold ([Table 3](#tbl3){ref-type="table"}). As PR silencing upregulated their expression, these genes represent transcriptional targets actively repressed by PR.

###### 

Unique genes whose expression was increased by PR-knock-down, and whose expression is therefore inhibited by liganded-PR. 24 genes showed changes in expression of 3-fold or more. 55 genes showed changes in expression of 2 to 3-fold. (In each case *n* = 4, *P* \< 0.0005, Adjusted *P* \< 0.05)

  ID              Gene symbol    Gene title                                                                Fold change in expression
  --------------- -------------- ------------------------------------------------------------------------- ---------------------------
  205680_at       MMP10          Matrix metallopeptidase 10 (stromelysin 2)                                7.617
  215867_x\_at    CA12           Carbonic anhydrase XII                                                    7.571
  223843_at       SCARA3         Scavenger receptor class A, member 3                                      6.989
  214799_at       NFASC          Neurofascin homologue (chicken)                                           6.311
  228155_at       C10orf57 58    Chromosome 10 open reading frame 57 and 58                                5.803
  203001_s\_at    STMN2          Stathmin-like 2                                                           5.511
  244353_s\_at    SLC2A12        Solute carrier family 2 (facilitated glucose transporter), member 12      5.277
  221019_s\_at    COLEC12        Collectin sub-family member 12                                            5.205
  214844_s\_at    DOK5           Docking protein 5                                                         4.276
  204638_at       ACP5           Acid phosphatase 5, tartrate resistant                                    4.16
  207016_s\_at    ALDH1A2        Aldehyde dehydrogenase 1 family, member A2                                3.915
  217525_at       OLFML1         Olfactomedin-like 1                                                       3.669
  220351_at       CCRL1          Chemokine (C-C motif) receptor-like 1                                     3.633
  213415_at       CLIC2          Chloride intracellular channel 2                                          2.95
  202580_x\_at    FOXM1          Forkhead box M1                                                           2.929
  209159_s\_at    NDRG4          NDRG family member 4                                                      2.862
  213001_at       ANGPTL2        Angiopoietin-like 2                                                       2.841
  243956_at       SUSD3          MRNA; cDNA DKFZp434J1812                                                  2.787
  235198_at       OSTM1          Osteopetrosis associated transmembrane protein 1                          2.768
  205347_s\_at    MGC39900       Thymosin beta15b///thymosin beta 15a                                      2.705
  220911_s\_at    KIAA1305       KIAA1305                                                                  2.613
  228890_at       ATOH8          Atonal homologue 8 (Drosophila)                                           2.585
  228436_at       KCNC4          Potassium voltage-gated channel, Shaw 4                                   2.578
  219937_at       TRHDE          Thyrotropin-releasing hormone degrading enzyme                            2.578
  1558537_x\_at   ZNF844         Zinc finger protein 844                                                   2.564
  1569157_s\_at   ZNF846         Zinc finger protein 846                                                   2.564
  218211_s\_at    MLPH           Melanophilin                                                              2.555
  226145_s\_at    FRAS1          Fraser syndrome 1                                                         2.513
  209539_at       ARHGEF6        Rac/Cdc42 guanine nucleotide exchange factor 6                            2.504
  213836_s\_at    WIPI1          WD repeat domain, phosphoinositide interacting 1                          2.462
  205730_s\_at    ABLIM3         Actin binding LIM protein family, member 3                                2.446
  209197_at       SYT11          Synaptotagmin XI                                                          2.444
  1552651_a\_at   RFFL           Ring finger and FYVE-like domain containing 1                             2.423
  235746_s\_at    PLA2R1         Phospholipase A2 receptor 1, 180 kD                                       2.414
  241723_at       IQGAP2         IQ motif containing GTPase activating protein 2                           2.412
  216603_at       SLC7A8         Solute carrier family 7 (cationic amino acid transporter, y+ system), 8   2.407
  210768_x\_at    TMCO1          Transmembrane and coiled-coil domains 1                                   2.398
  227048_at       LAMA1          Laminin, alpha 1                                                          2.394
  204236_at       FLI1           Friend leukaemia virus integration 1                                      2.393
  1563753_at      LOC149684      Hypothetical protein LOC149684                                            2.372
  205113_at       NEFM           Neurofilament, medium polypeptide                                         2.37
  204675_at       SRD5A1         Steroid-5-alpha-reductase, alpha polypeptide 1                            2.368
  209365_s\_at    ECM1           Extracellular matrix protein 1                                            2.364
  211343_s\_at    COL13A1        Collagen, type XIII, alpha 1                                              2.351
  204797_s\_at    EML1           Echinoderm microtubule associated protein like 1                          2.34
  224800_at       WDFY1          WD repeat and FYVE domain containing 1                                    2.327
  228438_at       LOC100132891   Homo sapiens hypothetical protein LOC100132891                            2.309
  203435_s\_at    MME            Membrane metallo-endopeptidase                                            2.302
  210291_s\_at    ZNF174         Zinc finger protein 174                                                   2.29
  232636_at       SLITRK4        SLIT and NTRK-like family, member 4                                       2.252
  207463_x\_at    PRSS3          Protease, serine, 3                                                       2.251
  213562_s\_at    SQLE           Squalene epoxidase                                                        2.248
  228728_at       C7orf58        Chromosome 7 open reading frame 58                                        2.241
  225412_at       TMEM87B        Transmembrane protein 87B                                                 2.227
  226106_at       RNF141         Ring finger protein 141                                                   2.201
  208703_s\_at    APLP2          Amyloid beta (A4) precursor-like protein 2                                2.197
  223395_at       ABI3BP         ABI family, member 3 (NESH) binding protein                               2.191
  244881_at       LMLN           Leishmanolysin-like (metallopeptidase M8 family)                          2.18
  213309_at       PLCL2          Phospholipase C-like 2                                                    2.18
  205603_s\_at    DIAPH2         Diaphanous homologue 2 (Drosophila)                                       2.164
  203666_at       CXCL12         Chemokine (C-X-C motif) ligand 12                                         2.137
  227188_at       C21orf63       Chromosome 21 open reading frame 63                                       2.084
  228253_at       LOXL3          Lysyl oxidase-like 3                                                      2.083
  213725_x\_at    XYLT1          Xylosyltransferase I                                                      2.053
  230256_at       C1orf104       Chromosome 1 open reading frame 104, mRNA                                 2.047
  1558680_s\_at   PDE1A          Phosphodiesterase 1A, calmodulin-dependent                                2.021
  205205_at       RELB           v-rel reticuloendotheliosis viral oncogene homologue B                    2.009
  212573_at       ENDOD1         Endonuclease domain containing 1                                          2.002

Ingenuity pathways analysis (IPA) showed that PR knock-down had the greatest effect on genes involved in cellular development, growth and proliferation. PR-induced genes were significantly enriched in two functional networks: (i) cellular development, growth proliferation and death (score 17 focus molecules 12); and (ii) cellular development, growth and proliferation, DNA replication, recombination and repair (score 15 focus molecules 11). Conversely, genes repressed by PR were significantly involved in three networks: (i) cell to cell signalling, inflammatory response, cellular movement (Score 21 focus molecules 15); (ii) cancer, cellular development, haematological system development (score 17, focus molecules 13); and (iii) skeletal muscular system development and function (score 15 focus molecules 12).

To explore the interactions between inflammatory signals and PR, myocytes in culture were incubated for 96 hrs with PR specific siRNA or non-targeting control siRNA, and then treated with MPA for a further 24 hrs. In the last 6 hrs of culture, cells were incubated with IL-1β (1 ng/ml) or vehicle control. We then compared the gene expression profiles of cells incubated with and without IL-1β in the absence of PR knock-down, i.e. transfected with non-targeting siRNA and in the presence of PR knock-down.

IL-1β activates myometrial inflammation
---------------------------------------

In cells exposed to non-targetting siRNA, IL-1β significantly regulated 5160 probe sets (*P* \< 0.05 with correction for multiple testing). Upon elimination of unannotated sequences and duplicate probe sets, 1440 (57%) and 1892 (43%) unique gene sequences were found to be up- and downregulated respectively. The expression of two genes, *CXCL2* and *CXCL3*, increased in excess of a 1000-fold. An additional 14 genes, mostly inflammatory in action, increased in expression ≥100-fold and 40 additional genes between 99- and 20-fold ([Table 4](#tbl4){ref-type="table"}). Of the 1892 repressed genes, 465 were inhibited ≥2-fold, which included 127 and 46 transcripts regulated ≥3 and 5-fold respectively ([Table 5](#tbl5){ref-type="table"}). The two probes complementary to PR mRNA on the array showed a 1.6- and 4.8-fold reduction in total PR transcript levels in response to IL-1β stimulation (*P* \< 0.0002). As anticipated, IPA confirmed that IL-1β signalling has the greatest effect on gene networks involved in inflammation, immunity, anti-microbial response and NF-κB signalling.

###### 

Unique genes whose expression was increased 20-fold or more by interleukin 1-beta. (In each case *n* = 4, *P* \< 0.0005, Adjusted *P* \< 0.05)

  ID              Gene symbol   Gene title                                                           Fold change in expression
  --------------- ------------- -------------------------------------------------------------------- ---------------------------
  209774_x\_at    CXCL2         Chemokine (C-X-C motif) ligand 2                                     1504.177
  207850_at       CXCL3         Chemokine (C-X-C motif) ligand 3                                     1008.501
  205476_at       CCL20         Chemokine (C-C motif) ligand 20                                      491.925
  211506_s\_at    IL8           Interleukin 8                                                        474.416
  204470_at       CXCL1         Chemokine (C-X-C motif) ligand 1                                     465.483
  204533_at       CXCL10        Chemokine (C-X-C motif) ligand 10                                    417.043
  202638_s\_at    ICAM1         Intercellular adhesion molecule 1                                    362.152
  223484_at       C15orf48      Chromosome 15 open reading frame 48                                  311.712
  202510_s\_at    TNFAIP2       Tumour necrosis factor, alpha-induced protein 2                      278.746
  205207_at       IL6           Interleukin 6 (interferon, beta 2)                                   205.52
  214974_x\_at    CXCL5         Chemokine (C-X-C motif) ligand 5                                     197.62
  202643_s\_at    TNFAIP3       Tumour necrosis factor, alpha-induced protein 3                      172.438
  208075_s\_at    CCL7          Chemokine (C-C motif) ligand 7                                       170.853
  203868_s\_at    VCAM1         Vascular cell adhesion molecule 1                                    144.993
  205067_at       IL1B          Interleukin 1, beta                                                  144.646
  204748_at       PTGS2         Prostaglandin-endoperoxide synthase 2                                103.175
  206336_at       CXCL6         Chemokine (C-X-C motif) ligand 6                                     95.875
  216598_s\_at    CCL2          Chemokine (C-C motif) ligand 2                                       93.106
  225516_at       SLC7A2        Solute carrier family 7, member 2                                    82.812
  207442_at       CSF3          Colony stimulating factor 3 (granulocyte)                            77.819
  210538_s\_at    BIRC3         Baculoviral IAP repeat-containing 3                                  73.068
  205681_at       BCL2A1        BCL2-related protein A1                                              72.539
  204798_at       MYB           v-myb myeloblastosis viral oncogene homologue (avian)                64.656
  204614_at       SERPINB2      Serpin peptidase inhibitor, clade B, member 2                        53.144
  209706_at       NKX3-1        NK3 homeobox 1                                                       51.161
  205680_at       MMP10         Matrix metallopeptidase 10 (stromelysin 2)                           48.891
  214038_at       CCL8          Chemokine (C-C motif) ligand 8                                       48.42
  217590_s\_at    TRPA1         Transient receptor potential cation channel, subfamily A, member 1   47.185
  215223_s\_at    SOD2          Superoxide dismutase 2, mitochondrial                                46.044
  222549_at       CLDN1         Claudin 1                                                            44.584
  205266_at       LIF           Leukaemia inhibitory factor                                          41.476
  220091_at       SLC2A6        Solute carrier family 2, member 6                                    40.655
  205027_s\_at    MAP3K8        Mitogen-activated protein kkk 8                                      36.936
  205013_s\_at    ADORA2A       Adenosine A2a receptor                                               36.636
  213524_s\_at    G0S2          G0/G1switch 2                                                        36.454
  229437_at       BIC           BIC transcript                                                       36.36
  209493_at       PDZD2         PDZ domain containing 2                                              35.692
  202357_s\_at    C2///CFB      Complement component 2 factor B                                      35.285
  823_at          CX3CL1        Chemokine (C-X3-C motif) ligand 1                                    35.275
  204224_s\_at    GCH1          GTP cyclohydrolase 1                                                 34.613
  204273_at       EDNRB         Endothelin receptor type B                                           34.355
  207386_at       CYP7B1        Cytochrome P450, 7B1                                                 34.197
  210133_at       CCL11         Chemokine (C-C motif) ligand 11                                      32.614
  231779_at       IRAK2         Interleukin-1 receptor-associated kinase 2                           31.006
  235122_at       HIVEP3        HIV type I enhancer binding protein 3                                28.811
  1555759_a\_at   CCL5          Chemokine (C-C motif) ligand 5                                       28.427
  228186_s\_at    RSPO3         R-spondin 3 homologue (Xenopus laevis)                               27.918
  218810_at       ZC3H12A       Zinc finger CCCH-type containing 12A                                 26.17
  203180_at       ALDH1A3       Aldehyde dehydrogenase 1 A3                                          25.876
  207510_at       BDKRB1        Bradykinin receptor B1                                               23.079
  225316_at       MFSD2         Major facilitator superfamily domain 2                               22.964
  206924_at       IL11          Interleukin 11                                                       22.963
  205798_at       IL7R          Interleukin 7 receptor                                               22.495
  205619_s\_at    MEOX1         Mesenchyme homeobox 1                                                21.495
  202902_s\_at    CTSS          Cathepsin S                                                          20.715
  206432_at       HAS2          Hyaluronan synthase 2                                                20.527

###### 

Unique genes whose expression was decreased 5-fold or more by interleukin 1-beta. (In each case *n* = 4, *P* \< 0.0005, Adjusted *P* \< 0.05)

  ID             Gene symbol    Gene title                                                           Fold change in expression
  -------------- -------------- -------------------------------------------------------------------- ---------------------------
  201009_s\_at   TXNIP          Thioredoxin interacting protein                                      −26.955
  226069_at      PRICKLE1       Prickle homologue 1 (Drosophila)                                     −11.959
  238029_s\_at   SLC16A14       Solute carrier family 16, member 14                                  −11.46
  209582_s\_at   CD200          CD200 molecule                                                       −10.727
  204424_s\_at   LMO3           LIM domain only 3 (rhombotin-like 2)                                 −10.248
  225171_at      ARHGAP18       Rho GTPase activating protein 18                                     −10.094
  221911_at      ETV1           Ets variant 1                                                        −9.948
  220002_at      KIF26B         Kinesin family member 26B                                            −9.665
  239710_at      FIGN           Fidgetin                                                             −9.57
  225548_at      SHROOM3        Shroom family member 3                                               −9.142
  235085_at      PRAGMIN        Homologue of rat pragma of Rnd2                                      −8.716
  229674_at      SERTAD4        SERTA domain containing 4                                            −8.512
  206528_at      TRPC6          Transient receptor potential cation channel, C6                      −8.502
  227812_at      TNFRSF19       Tumour necrosis factor receptor superfamily, 19                      −8.113
  226492_at      SEMA6D         Sema domain, transmembrane domain (TM), and cytoplasmic domain, 6D   −7.632
  206448_at      ZNF365         Zinc finger protein 365                                              −7.578
  233533_at      KRTAP1-5       Keratin associated protein 1-5                                       −7.45
  235591_at      SSTR1          Somatostatin receptor 1                                              −7.312
  1552508_at     KCNE4          Potassium voltage-gated channel, Isk- 4                              −7.278
  219935_at      ADAMTS5        ADAM metallopeptidase with thrombospondin type 1 motif, 5            −7.264
  242396_at      LOC100132798   Full length insert cDNA clone ZD42A11                                −6.852
  225977_at      PCDH18         Protocadherin 18                                                     −6.798
  229092_at      NR2F2          Nuclear receptor subfamily 2, group F, member 2                      −6.79
  222853_at      FLRT3          Fibronectin leucine rich transmembrane protein 3                     −6.775
  229114_at      GAB1           GRB2-associated binding protein 1                                    −6.536
  235956_at      KIAA1377       KIAA1377                                                             −6.523
  235476_at      TRIM59         Tripartite motif-containing 59                                       −6.494
  209292_at      ID4            Id-related helix-loop-helix protein Id4                              −6.343
  241752_at      SLC8A1         Solute carrier family 8, member 1                                    −6.338
  218087_s\_at   SORBS1         Sorbin and SH3 domain containing 1                                   −6.157
  207233_s\_at   MITF           Microphthalmia-associated transcription factor                       −6.111
  242794_at      MAML3          Mastermind-like 3 (Drosophila)                                       −6.049
  225816_at      PHF17          PHD finger protein 17                                                −5.908
  243140_at      ACTA2          Actin, alpha 2, smooth muscle, aorta, transcript variant 1           −5.816
  231881_at      CALD1          Caldesmon 1                                                          −5.794
  219619_at      DIRAS2         DIRAS family, GTP-binding RAS-like 2                                 −5.739
  228821_at      ST6GAL2        ST6 beta-galactosamide alpha-2,6-sialyltranferase 2                  −5.678
  226677_at      ZNF521         Zinc finger protein 521                                              −5.61
  222662_at      PPP1R3B        Protein phosphatase 1, regulatory (inhibitor) subunit 3B             −5.588
  209815_at      PTCH1          Patched homologue 1 (Drosophila)                                     −5.508
  204338_s\_at   RGS4           Regulator of G-protein signalling 4                                  −5.377
  203373_at      SOCS2          Suppressor of cytokine signalling 2                                  −5.312
  205304_s\_at   KCNJ8          Potassium inwardlyrectifying channel, J8                             −5.28
  209829_at      FAM65B         Family with sequence similarity 65, member B                         −5.164
  204529_s\_at   TOX            Thymocyte selection-associated high mobility group box               −5.051
  223599_at      TRIM6          Tripartite motif-containing 6                                        −5.042

IL-1β inhibits PR expression and microarray validation
------------------------------------------------------

The array analysis indicated that IL-1β inhibits *PR* expression in human myocytes. To validate the array, we performed Western analysis to examine the regulation of PR upon MPA and IL-1β stimulation in four independent primary myocyte cultures. IL-1β caused a significant reduction in the expression of both PR-B and PR-A upon 6 and 24 hrs of stimulation ([Fig. 1](#fig01){ref-type="fig"}C). This was associated with increased phosphorylation of p65, reflecting NF-κB activation, which peaked at 15 min., but persisted after 6 and 24 hrs ([Fig. 1](#fig01){ref-type="fig"}B). We further validated a set of selected genes regulated in a PR- and/or IL-1β-dependent manner by RTQ-PCR. These were selected arbitrarily in three groups: genes upregulated by both PR-knock-down and IL-1β stimulation; *MMP1*, *MMP3*, *MMP10:* genes upregulated by PR-knock-down; *COLEC12*, *STMN2*, *SCRA3*, *RXFP1*; and genes downregulated by PR-knock-down *THBS1*, *KCNJ2*, *COL12A1* and *TRPC6* ([Fig. 1](#fig01){ref-type="fig"}D). For these genes, the pattern of expression measured by RTQ-PCR analysis was in keeping with the array data.

Activation of myometrial inflammation antagonizes PR-induced gene expression
----------------------------------------------------------------------------

We next tested if inflammatory signal intermediates, activated by IL-1β, repress PR-dependent gene expression in human myocytes. If activation of myometrial inflammation causes 'functional progesterone withdrawal', then it would be expected that IL-1β stimulation would have similar effects on PR-dependent gene expression as knock-down of the receptor. We therefore cross-referenced the effects of IL-1β on the expression of the 279 unique genes regulated upon PR-knock-down. Although we found a significant positive correlation between the overall effect of PR silencing on myometrial gene expression and IL-1β stimulation this correlation was weak ([Fig. 2](#fig02){ref-type="fig"}A, Pearson\'s *r* = 0.4288, 95% confidence interval: 0.33--0.52, *P* \< 0.0001).

![(A) Correlation between the effect of incubation with IL1b and siRNA PR-knock-down upon all 276 genes whose expression was found to be regulated by PR (*r* = 0.4288, *P* \< 0.0001). (B) Correlation between the effect of incubation with IL1b and siRNA PR-knock-down upon the 118 genes whose expression was found to be decreased by PR-knock-down (*r* = 0.44, *P* \< 0.0001). Heatmaps compare effect of IL1b and siRNA PR-knock-down organized by (left panel) descending effect of siRNA PR-knock-down and (right panel) into gene groups similarly and oppositely regulated by IL1b and siRNA PR-knock-down. (C) Correlation between the effect of incubation with IL1b and siRNA PR-knock-down upon the 158 genes whose expression was found to be increased by PR-knock-down. Dotted line shows correlation if MMP10 is omitted from analysis. Heatmap compares effect of IL1b and siRNA PR-knock-down organized by descending effect of siRNA PR-knock-down. (D) Correlation between the effect of incubation with IL1b and siRNA PR-knock-down upon the 1440 genes whose expression was found to be increased by IL1b. (E) Correlation between the effect of incubation with IL1b and siRNA PR-knock-down in the presence of IL1b upon the 1440 genes whose expression was found to be increased by IL1b.](jcmm0016-2487-f2){#fig02}

We then focused on those genes whose expression was repressed by PR knock-down, thus induced in a PR-dependent fashion. This showed a correlation with IL-1β-dependent gene expression ([Fig. 2](#fig02){ref-type="fig"}B, Pearson\'s *r* = 0.4420, 95% confidence interval: 0.28--0.58; *P* \< 0.0001). The correlation became stronger if the analysis was confined to those genes repressed ≥2-fold upon PR knock-down (Pearson\'s *r* = 0.52, 95% confidence interval 0.27--0.7, *P* \< 0.003; data not shown).

Heatmapping ([Fig. 2](#fig02){ref-type="fig"}B) demonstrated a clear cassette of genes whose expression was repressed by PR knock-down (thus induced in a PR-dependent fashion), and also repressed by IL-1β which are therefore co-regulated. If adjustment is made for multiple comparisons then 42 of 118 genes (22%) repressed by PR knock-down were also significantly repressed by IL-1β (at *P* \< 0.05). However, a further 19 genes were also repressed by IL-1β at *P* \< 0.05 where single testing only was taken into account making a total of 61 of 188 genes (32%).

When those genes were analysed whose expression increased upon PR knockdown (i.e. inhibited by PR), the correlation with the IL-1β-dependent transcriptional response, although still significant was very weak ([Fig. 2](#fig02){ref-type="fig"}C, Pearson\'s *r* = 0.35, 95% confidence interval: 0.2--0.48, *P* \< 0.0001) and was entirely dependent upon the strong induction of a single gene, *MMP10*, in response to IL-1β and upon PR-knock-down. Omitting MMP10 from the analysis indicated that IL-1β-dependent activation of myometrial inflammation has no significant effect on the ability of PR to repress specific gene sets (*P* = 0.57).

PR does not repress pro-inflammatory gene networks induced by IL-1β
-------------------------------------------------------------------

We next hypothesized that PR, liganded or not, may serve to repress inflammatory genes in otherwise unstimulated myocytes. If so, PR silencing in the absence of inflammatory stimulation should be sufficient to regulate genes which are inducible by IL-1β. Alternatively, it is possible that PR only confers transcriptional repression of genes involved in myometrial inflammation upon exposure to inflammatory cues. If this hypothesis holds true then PR knock-down should further increase the expression of genes induced by IL-1β treatment.

To explore the first hypothesis, we correlated the effect of PR knock-down in unstimulated myocytes on expression of genes which would be activated upon IL-1β treatment. No correlation was found ([Fig. 2](#fig02){ref-type="fig"}D). Of 1440 genes induced by IL-1β in human myocytes, PR silencing significantly increased the expression of only 36 (0.025%) genes, and just 15 of these by ≥2-fold. We then explored the second hypothesis, but again no correlation was found ([Fig. 2](#fig02){ref-type="fig"}E). PR-knock-down failed to significantly augment the vast majority of genes induced by IL-1β stimulation. The expression of only 39 (0.027%) of 1440 IL-1β-induced genes was significantly enhanced upon prior PR silencing, with transcript levels of merely 22 of these upregulated by ≥2-fold.

In the absence of a 'global' anti-inflammatory role for PR, we speculated that this nuclear receptor may still be important for the repression of a discrete cassette of genes encoding key inflammatory mediators. We therefore focussed on those IL-1β upregulated genes whose expression increases upon PR silencing in both stimulated and unstimulated cells. Only seven such genes were identified from the microarray analysis ([Table 6](#tbl6){ref-type="table"}). Furthermore, for all but one gene, *MMP10*, the increase caused by IL-1β alone and additional increase in transcript levels caused by PR knock-down in the presence or absence of IL-1β was modest, albeit significant. One gene, MMP1, showed a similar pattern of expression to MMP10, but on the microarray analysis whilst the effect of IL-1β, and PR knock-down in the presence of IL-1β was significant, the effect of PR knock-down alone was significant for single testing but not when multiple testing was taken into account. We selected this gene for independent validation studies and found that, in those studies using qRT-PCR, the effects of IL-1β, PR knock-down alone and PR knock-down in the presence of IL-1β were all significant ([Fig. 1](#fig01){ref-type="fig"}D).

###### 

Unique IL1b upregulated genes whose expression was increased in unstimulated cells by PR-knock-down (siRNA/PR FC i.e fold change), and further increased by PR-knock-down in the presence of IL1b (siRNA/PR + IL1b FC i.e fold change). (In each case *n* = 4, *P* \< 0.0005, Adjusted *P* \< 0.05)

  ID             Gene Symbol   Gene name                              Fold increase IL1β   Fold increase siPR *versus* control    Fold increase siPR + IL1β v IL1β alone
  -------------- ------------- -------------------------------------- -------------------- -------------------------------------- ----------------------------------------
  205680_at      MMP10         Matrix metallopeptidase 10             48.9                 7.6                                    8
  204475_at      MMP1          Matrix metallopeptidase 1              16                   5.8[\*](#tf6-1){ref-type="table-fn"}   6.4
  218330_s\_at   NAV2          Neuron navigator 2                     2.2                  3.4                                    2.5
  209960_at      HGF           Hepatocyte growth factor               6.2                  2.6                                    2.8
  213562_s\_at   SQLE          Squalene epoxidase                     2.7                  2.2                                    1.8
  223395_at      ABI3BP        ABI family, 3 (NESH) binding protein   1.6                  2.2                                    2.3
  213725_x\_at   XYLT1         Xylosyltransferase I                   1.6                  2.1                                    1.9

Significant for single but not multiple testing.

Discussion
==========

Understanding the mechanism of the onset of human parturition is critical for the design of strategies to predict and prevent preterm birth. However, this requires more than simply understanding the mechanisms of contractions. Although a range of drugs is available which are intended to inhibit uterine contractions their clinical effectiveness is disappointing. The 'tocolytic' reactive management of preterm labour is giving way to a strategy based upon prediction and prevention, however, the only agent which currently shows promise in preventing the onset of preterm labour is progesterone. Progesterone appears to be effective in some woman at high risk of preterm birth with a singleton pregnancy, but does not reduce the risk of prematurity in multiple pregnancy \[[@b12]\]. Further development of progestational agents and similar drugs for this indication requires a better understanding of the function of progesterone and its receptor within the uterus.

We have modelled PR-mediated functional progesterone withdrawal by using siRNA knock-down of PR in the presence of a synthetic progesterone. Comparisons were made between siRNA/PR and control always in the presence of synthetic progesterone. We did not compare gene expression between cells in the presence or absence of progesterone as there is no withdrawal of progesterone in association with human labour and therefore, *in vivo*, there is always PR ligand present. We have used MPA rather than natural progesterone because of its greater long-term stability in culture. MPA has been reported to have glucocorticoid receptor activity \[[@b13]\], but we have found that this also applies to natural progesterone \[[@b14]\]. Use of siRNA requires the use of passaged cells in culture, as it is not possible to obtain sufficient cells numbers for experimental purposes without passage. Such models are widely used in investigation of myometrial cell function, however, they do risk the possibility that cultures become enriched for rapidly dividing fibroblast cells and there is loss of the extracellular matrix integrity and cell-matrix interaction of the intact tissue. We have confirmed that our cell cultures after passage and MPA incubation are alpha-actin and oxytocin receptor positive and that expression of PR and the PR-A:PR-B ratio is similar to that seen in fresh myometrial tissue. A caveat to this, however, is that we have found some patient to patient variability in PR-A:PR-B ratio in both myometrial tissue taken at pre-labour caesarean section and subsequent cell culture which may be dependent upon how close the individual woman is to the onset of labour.

Progesterone is widely thought to act principally to repress contractions through repressing 'contraction-associated proteins'. However, it is now clear that progesterone plays a more complex role in myometrial physiology during pregnancy. In the rat, progesterone is involved in phenotypic modulation of myocytes during the synthetic phase of myometrial differentiation in the last third of pregnancy during which there is myometrial hypertrophy and synthesis and deposition of interstitial matrix \[[@b15]\]. We found that in human myocytes PR regulates a relatively small number of genes. We did not see significant down-regulation of classic 'contraction-associated proteins' by PR. The major effect of PR upon gene expression was upon genes concerned with cellular development, growth and proliferation. PR also highly upregulates two ion channels; transient receptor potential canonical-6 (TRPC-6) and the inward-rectifier potassium ion channel KCNJ2. TRPC channels in general mediate store-operated calcium entry. Expression of TrpC1, TrpC3, TrpC4 and TrpC6 has been demonstrated in human myometrium \[[@b16]\]. Tonic stretch co-regulates calcium entry pathways and TRPC3 and TRPC4 expression suggesting that these receptors play a role in increasing contractility \[[@b17]\]. Trp6, however, differs in that it mediates non-store operated calcium entry and TrpC6 has been shown to play an essential role in cellular proliferation in a range of cell types \[[@b18], [@b19]\].

Fibronectin leucine rich transmembrane protein-3 (FLRT-3), and thrombospondin 1 (THBS1) were found to be highly upregulated by PR whilst matrix metallopeptidase 10 (MMP-10) was highly repressed. FLRT3 is a member of the fibronectin leucine rich transmembrane protein family which play important roles in cell matrix adhesion. THBS1 is an adhesive glycoprotein which binds fibrinogen, fibronectin, laminin, collagen and integrins and also mediates cell-to-matrix interactions. MMP-10 is a member of the matrix metalloproteinase family which is involved in the breakdown of extracellular matrix. Collectively, these data point to a role for PR regulated genes in the synthesis and maintenance of interstitial matrix in the human. PR therefore probably acts during pregnancy more to regulate the growth and development of the uterus than to directly inhibit contractions, which is consistent with progesterone having efficacy as a prophylactic agent, but not as a tocolytic agent.

Our principal purpose was to shed light on the inter-relationship between PR and the myometrial inflammation. Parturition can be thought of, at least in part, as inflammatory in nature as it is associated with upregulation of prostaglandin, cytokine and chemokine synthesis with the uterus and with an influx of macrophages and lymphocytes into the myometrium and cervix \[[@b20]\]. Although the inflammatory cell infiltrate may be a source of cytokines within the labouring uterus it is clear that myometrium itself is a major source of inflammatory mediators \[[@b21]\]. IL-1β concentrations rise within the uterus in association with both term and preterm labour \[[@b22]\]. We activated myometrial inflammation by incubation with IL-1β which activates both NF-κB and AP-1 leading to upregulation of a wide variety of inflammatory genes which have been shown to be associated with parturition \[[@b23], [@b24]\]. As would be expected we found that IL-1β increased expression of genes involved in immunity, inflammation, anti-microbial response and NF-κB signalling.

Seminal studies of the endocrinology of parturition in sheep and rodent models suggested that progesterone withdrawal is an early initiating factor leading to subsequent upregulation of 'inflammatory' type mediators, most importantly prostaglandins. This would suggest that progesterone acts to inhibit the inflammatory biochemistry of parturition. One hypothesis of the mechanism of human parturition suggests that the activation of inflammation occurs late in the process of parturition and that its principal role is the involution of the uterus following delivery. However, there is growing evidence that inflammation is an early initiating event in human parturition which begins before the onset of contractions. Activation of NF-κB within the uterus appears to play an important role in the onset of labour, and in the myometrium principally regulates a group of immune/inflammation associated genes \[[@b8], [@b21], [@b25]\].

Condon *et al*. \[[@b5]\] have shown no activation of NF-κB in myometrium in the third trimester of pregnancy remote from the onset of labour. However, in a study in which we compared tissue samples from women taken either before or after labour at term we found that that NF-κB is active in myocytes in both the upper and lower segment of the uterus prior to the onset of labour at term \[[@b21]\]. This, taken together with data which shows that inhibition of NF-κB in the mouse prevents normal term labour \[[@b8]\] suggest that NF-κB begins to be activated in myometrium close to, but prior to, the onset of labour at term. This concept is supported by the results of mathematical modelling studies \[[@b26]\], which explored three main hypotheses for the activation of the human uterus at labour: functional progesterone withdrawal; inflammatory stimulation; and oxytocin receptor activation. These were modelled using gene expression data in pre-labour myometrial samples using directed graphs. It was found that inflammatory activation as a primary event in parturition was highly likely, progesterone withdrawal, as a primary event, was less likely but plausible, and that oxytocin receptor mediated initiation was unlikely.

We considered three non-mutually exclusive hypotheses concerning the interaction between inflammation and PR in myocytes. These were that inflammation acts to repress the function of PR; that liganded PR acts to repress basal expression of inflammatory mediators; or that liganded PR acts to repress stimulated expression of inflammatory mediators in myocytes. Our data shows that activation of inflammation does act to inhibit PR function, but, in general only in relation to genes which are upregulated, not downregulated by PR. Specifically, we identified a cassette of genes, representing some 20--30% of genes upregulated *via* PR that are downregulated by activation of inflammation. This is possibly a consequence of the different ways in which PR interacts with co-factors and the promoters of genes which are either up- or downregulated. There was, however, no general anti-inflammatory effect of activated PR either upon basal or stimulated expression of inflammatory mediators. We identified a few genes which were oppositely regulated by inflammation or PR, most significantly the matrix-metalloproteinases, MMP10 and MMP3, but not cytokines, chemokines or 'contraction-associated proteins'. The genes neuron navigator 2, hepatocyte growth factor, squalene epoxidase, ABI family, 3 (NESH) binding protein and xylosyltransferase I were each found to be oppositely regulated by inflammation or PR, but the overall effect of either IL-1β or PR-knock-down was very small when compared with those effects in relation to MMP1 or MMP10. It is doubtful that the opposite regulation of these six genes by inflammation or PR is of significance in the context of parturition. Interestingly, although progesterone has been shown to inhibit IL-1β stimulated expression of prostaglandin-endoperoxide synthase type-2 and interleukin-8 in human myocytes, uterine fibroblasts and amnion cells \[[@b11], [@b27]\] in the current study PR-knock-down did not enhance the IL-1β stimulated expression of either of these genes suggesting that the effect of progesterone in this context is not mediated *via* PR. Progesterone itself may nevertheless have a greater anti-inflammatory role within the uterus, but mediated through receptors other than PR \[[@b14]\].

Our data are consistent with activation of inflammation being a significant mediator of functional-progesterone withdrawal in the context of the PR mediated action of progesterone. There are several mechanisms, which may act together, by which inflammation may repress PR function. In the present study, we found that IL-1β caused a significant downregulation in expression of PR itself although not a change in the ratio of PR-B to PR-A. Mesiano *et al*. \[[@b1], [@b2]\] have suggested that it is a change in the ratio of the PR-B to PR-A isoforms of PR which leads to functional-progesterone withdrawal and have shown that this may be mediated by increased prostaglandin synthesis. As would be expected, we found that incubation with IL-1β leads to a large increase in prostaglandin-endoperoxide synthase type-2 expression. However, it is unlikely that inhibition of PR synthesis is the sole mechanism since at the 6-hr time point examined PR expression had reduced by only one-third. Furthermore, the effect of IL-1β upon PR regulated genes was only upon those upregulated, suggesting a mechanism other than simple receptor withdrawal. That it is likely that NF-κB is activated within the uterus early in the biochemical events of labour suggests that the negative interaction between NF-κB p65 and PR may also represent an important mechanism of functional-progesterone withdrawal. Activation of NF-κB leads to increased synthesis of its own p65 (RelA) subunit and to increased synthesis of IL-1β and so to a positive feed forward loop in which there is both synthesis and activation (phosphorylation) of p65 and therefore repression of PR. Our data supports inhibition of PR by inflammation in general, or NF-κB specifically, but suggests that the negative interaction between NF-κB p65 and PR does not function in myometrium in the opposite direction as we found no evidence of PR acting to repress NF-κB regulated genes.

Much of what is currently known about the endocrinology and biochemistry of parturition has come from animal models, however, human parturition is unusual in that circulating progesterone levels do not fall until after delivery \[[@b2]\]. Ethical considerations mostly limit *in vivo* experiments in humans to observations. Studies involving manipulation of endocrine or inflammatory factors in humans are very difficult to undertake *in vivo* and so need to be modelled *in vitro*. Inevitably, no model can take into account all of the complex endocrine, paracrine and mechanical factors which interact in the uterus *in vivo*. The model that we developed for this study was made as simple as possible to answer our key questions: what are the genes regulated by PR in the myocyte in the presence of progesterone and how does PR-function and inflammation interact. Overall the data that we present here support the concept that progesterone acts through PR in human myocytes to mediate cellular development, growth and proliferation and maintain the interstitial matrix, but that progesterone does not play a significant anti-inflammatory role *via* PR. Conversely inflammation does act to generally inhibit expression of genes which are upregulated by PR. This is consistent with a hypothesis for the mechanism of human parturition in which activation of inflammatory mediators, likely through activation of NF-κB, is an early event preceding 'functional progesterone withdrawal'.
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